Aida Pharmaceuticals (AIDA)

[QFA2008]

Aida use cash to buy JSIM and they said it is important for Adia to buy JSIM:
1. IP of Etimicin: some company manufacture Etimicin without IP. Buy JSIM will finally resolve this issue.
2. Wetimicin – next generation Aminoglycoside antibiotic, almost done Phase I and will start phase II soon. If Aida own JSIM, these is no any IP issue like Etimicin and Wetimicin is class I drug in China. Aminoglycoside antibiotic has huge markit in China and outside of China.
3. JSIM has a lot of scientists and engineers; and has a lot of on going projects. It will be a big benefit for Aida.

I think this acquisition is win-win for both Aida and JSIM.